Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes

Mahdie Hemati,1,2 Fateme Haghiralsadat,2,3 Farzaneh Jafary,1 Seyedmohammad Moosavizadeh,4 Ali Moradi11Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 2Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hemati M, Haghiralsadat F, Jafary F, Moosavizadeh S, Moradi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Niosome siRNA CDC20 Doxorubicin Quercetin Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/85f47e8a6a4d4c58a9f1ef2daa0f16b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85f47e8a6a4d4c58a9f1ef2daa0f16b1
record_format	dspace
spelling	oai:doaj.org-article:85f47e8a6a4d4c58a9f1ef2daa0f16b12021-12-02T04:51:36ZTargeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes1178-2013https://doaj.org/article/85f47e8a6a4d4c58a9f1ef2daa0f16b12019-08-01T00:00:00Zhttps://www.dovepress.com/targeting-cell-cycle-protein-in-gastric-cancer-with-cdc20sirna-and-ant-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Mahdie Hemati,1,2 Fateme Haghiralsadat,2,3 Farzaneh Jafary,1 Seyedmohammad Moosavizadeh,4 Ali Moradi11Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 2Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 3Department of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 4Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, IranBackground and purpose: In a past study, we developed and optimized a novel cationic PEGylated niosome containing anticancer drugs (doxorubicin or quercetin) and siRNA. This study intended to evaluate the anti-tumor effects of the combination therapy to target both the proteins and genes responsible for the development of gastric cancer. CDC20, known as an oncogene, is a good potential therapeutic candidate for gastric cancer.Methods: In order to increase the loading capacity of siRNA and achieve appropriate physical properties, we optimized the cationic PEGylated niosome in terms of the amount of the cationic lipids. Drugs (doxorubicin and quercetin) and CDC20siRNA were loaded into the co-delivery system, and physical characteristics, thermosensitive controlled-release, gene silencing efficiency, and apoptosis rate were determined.Results: The results showed that the designed co-delivery system for the drugs and gene silencer had an appropriate size and a high positive charge for loading siRNA, and also showed a thermosensitive drug release behavior, which successfully silenced the CDC20 expression when compared with the single delivery of siRNA or the drug. Moreover, the co-delivery of drugs and CDC20siRNA exhibited a highly inhibitory property for the cell growth of gastric cancer cells.Conclusion: It seems that the novel cationic PEGylated niosomes co-loaded with anticancer drug and CDC20siRNA has a promising application for the treatment of gastric cancer.Keywords: niosome, siRNA, CDC20, doxorubicin, quercetinHemati MHaghiralsadat FJafary FMoosavizadeh SMoradi ADove Medical PressarticleNiosomesiRNACDC20DoxorubicinQuercetinMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 6575-6585 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Niosome siRNA CDC20 Doxorubicin Quercetin Medicine (General) R5-920
spellingShingle	Niosome siRNA CDC20 Doxorubicin Quercetin Medicine (General) R5-920 Hemati M Haghiralsadat F Jafary F Moosavizadeh S Moradi A Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
description	Mahdie Hemati,1,2 Fateme Haghiralsadat,2,3 Farzaneh Jafary,1 Seyedmohammad Moosavizadeh,4 Ali Moradi11Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 2Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 3Department of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; 4Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, IranBackground and purpose: In a past study, we developed and optimized a novel cationic PEGylated niosome containing anticancer drugs (doxorubicin or quercetin) and siRNA. This study intended to evaluate the anti-tumor effects of the combination therapy to target both the proteins and genes responsible for the development of gastric cancer. CDC20, known as an oncogene, is a good potential therapeutic candidate for gastric cancer.Methods: In order to increase the loading capacity of siRNA and achieve appropriate physical properties, we optimized the cationic PEGylated niosome in terms of the amount of the cationic lipids. Drugs (doxorubicin and quercetin) and CDC20siRNA were loaded into the co-delivery system, and physical characteristics, thermosensitive controlled-release, gene silencing efficiency, and apoptosis rate were determined.Results: The results showed that the designed co-delivery system for the drugs and gene silencer had an appropriate size and a high positive charge for loading siRNA, and also showed a thermosensitive drug release behavior, which successfully silenced the CDC20 expression when compared with the single delivery of siRNA or the drug. Moreover, the co-delivery of drugs and CDC20siRNA exhibited a highly inhibitory property for the cell growth of gastric cancer cells.Conclusion: It seems that the novel cationic PEGylated niosomes co-loaded with anticancer drug and CDC20siRNA has a promising application for the treatment of gastric cancer.Keywords: niosome, siRNA, CDC20, doxorubicin, quercetin
format	article
author	Hemati M Haghiralsadat F Jafary F Moosavizadeh S Moradi A
author_facet	Hemati M Haghiralsadat F Jafary F Moosavizadeh S Moradi A
author_sort	Hemati M
title	Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
title_short	Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
title_full	Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
title_fullStr	Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
title_full_unstemmed	Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes
title_sort	targeting cell cycle protein in gastric cancer with cdc20sirna and anticancer drugs (doxorubicin and quercetin) co-loaded cationic pegylated nanoniosomes
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/85f47e8a6a4d4c58a9f1ef2daa0f16b1
work_keys_str_mv	AT hematim targetingcellcycleproteiningastriccancerwithcdc20sirnaandanticancerdrugsdoxorubicinandquercetincoloadedcationicpegylatednanoniosomes AT haghiralsadatf targetingcellcycleproteiningastriccancerwithcdc20sirnaandanticancerdrugsdoxorubicinandquercetincoloadedcationicpegylatednanoniosomes AT jafaryf targetingcellcycleproteiningastriccancerwithcdc20sirnaandanticancerdrugsdoxorubicinandquercetincoloadedcationicpegylatednanoniosomes AT moosavizadehs targetingcellcycleproteiningastriccancerwithcdc20sirnaandanticancerdrugsdoxorubicinandquercetincoloadedcationicpegylatednanoniosomes AT moradia targetingcellcycleproteiningastriccancerwithcdc20sirnaandanticancerdrugsdoxorubicinandquercetincoloadedcationicpegylatednanoniosomes
_version_	1718401018696302592

Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes

Ejemplares similares